January 20 2012 Carolus Therapeutics Reports Publication of Preclinical Data for CT-2009 Supporting Development in Acute Lung Injury

SAN DIEGO, Jan. 20, 2012 /PRNewswire via COMTEX/ — Carolus Therapeutics, Inc. today announced the publication of preclinical data showing that CT-2009 disrupts heteromers formed by the platelet-derived chemokines CCL5 (RANTES) and CXCL4, thereby preventing lung damage in multiple mouse models of acute lung injury (ALI). The study, published online on the website of the American Journal of Respiratory and Critical Care Medicine (AJRCCM), showed that CCL5-CXCL4 chemokine heteromers are associated with platelet-dependent recruitment of neutrophils, increased lung permeability and tissue damage.


Neutrophils are thought to be important disease effector cells in ALI as well as other respiratory conditions. Inhibiting these chemokine heteromers with CT-2009 strongly diminished recruitment of neutrophils to the lung, lung permeability changes, and tissue damage. In lung tissue samples from both human patients and mice with ALI, lung neutrophil counts were highly correlated with chemokine heteromer concentrations, providing strong support for the CT-2009 chemokine heteromer target having an important pathological role in ALI and translation of the mouse model results to human disease.

Read the entire article at:


or go to www.ipftoday.com for more information and news.


This entry was posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized and tagged , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>